US FDA’s Cimerli Review By The Numbers

 
• By Sue Sutter
  
Drug Review Profile: Cimerli Chronology
Cimerli was the second biosimilar version of Lucentis approved in the US but the first deemed interchangeable. • Source: Shutterstock/Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics